期刊文献+

帕瑞昔布钠用于鼻内镜手术后镇痛效果的临床观察 被引量:12

暂未订购
导出
摘要 目的:评价鼻内镜手术术毕时单次静脉注射帕瑞昔布钠的术后镇痛效果。方法:择期全麻下行鼻内镜手术患者60例,随机分成帕瑞昔布钠组(P组,n=30)和对照组(C组,n=30)。连续监测血流动力学,分别于术毕即刻(T0)、拔管前10min(T1)、拔管即刻(T2)、拔管后10min(T3),记录SP、DP、MAP、HR并计算RPP,于术后2、4、8、12、24h记录VAS评分,并记录术后24h内患者对疼痛的总体印象及不良反应。结果:P组T0时点SP、DP、MAP、HR、RPP与C组差异无统计学意义,T1、T3时点SP、DP、MAP、HR、RPP明显低于C组(P<0.05)。与T0时点相比,C组T1、T2、T3时点SP、DP、MAP、HR、RPP明显升高(P<0.05)。P组各时点VSA评分明显低于C组(P<0.05)。24h内对疼痛的总体印象P组低于C组。P组与C组相比不良反应无显著差异。结论:帕瑞昔布钠用于鼻内镜术后镇痛效果好、安全、有效。
出处 《实用医学杂志》 CAS 北大核心 2010年第18期3416-3417,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献4

二级参考文献16

  • 1BOMBARDIER C, LAINE L, REICIN A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group[ J]. N Engl J Med, 2000, 343(21 ) :1520 - 1528.
  • 2SCHNITZER TJ, BURMESTER GR, MYSLER E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TAR- GET), reduction in ulcer complications: randomised controlled trial[ J]. Lancet, 2004, 364(9435 ) :665 - 674.
  • 3SILVERSTEIN FE, FAICH G, GOLDSTEIN JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS stud- y: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study[ J]. JAMA, 2000, 284 (10) : 1247 - 1255.
  • 4LAINE L, CURTIS SP, CRYER B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison [ J ]. Lancet, 2007, 369 (9560) :465 - 473.
  • 5BRESALIER RS, SANDLER RS, QUAN H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma che- moprevention trial[ J ]. N Engl J Med, 2005, 352 (11 ) :1092 - 1102.
  • 6BERTAGNOLLI MM, EAGLE C J, ZAUBER AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas [ J ]. N Engl J Med, 2006, 355 ( 9 ) :873 - 884.
  • 7KEARNEY PM, BAIGENT C, GODWIN J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials [ J]. BMJ, 2006, 332 (7553) : 1302 - 1308.
  • 8MCGETTIGAN P, HENRY D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 [J]. JAMA, 2006, 296(13): 1633 -1644.
  • 9HINZ B, RENNER B, BRUNE K. Drug insight: cyclo-oxygenase-2 inhibitors a critical appraisal [ J ]. Nat Clin Pract Rheumatol, 2007, 3 (10) :552 - 560.
  • 10ZANCHETTI A, HANSSON L, DAHLOF B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group[ J]. J Hypertens, 2001, 19 (6) :1149 - 1159.

共引文献31

同被引文献85

引证文献12

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部